Literature DB >> 12197473

Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes.

Y Duraisamy1, M Slevin, N Smith, J Bailey, J Zweit, C Smith, N Ahmed, J Gaffney.   

Abstract

Ineffectual wound healing in hyperglycaemic patients suffering from diabetes mellitus is characterised by a reduction in capillary reformation (angiogenesis). Basic fibroblast growth factor (FGF-2) is secreted by fibroblasts, macrophages and in particular endothelial cells (EC) in response to tissue injury and is important in promotion of neovascularisation. Recently, glycation of FGF-2 has been shown to significantly reduce its activity in vitro. We have examined the kinetics of FGF-2 glycation and compared its ability with that of native FGF-2 to activate mitogenesis, capillary formation and associated signal transduction in bovine aortic EC (BAEC). FGF-2 was exposed to 0.25 M glucose-6-phosphate (G-6-P) for 24-72 h and the degree of glycation determined by matrix assisted laser desorption ionisation mass spectrometry. Native FGF-2 was heterogeneous with Mw in the range 15,153.6-17,903 Da. After 24 h incubation with G-6-P there was evidence of glycation, and the mass increase corresponded to addition of 2.7 mol of G-6-P residues; after 48 h, 4 mol sugar was added and this increased to 8.7 after 72 h. Dimerisation of FGF-2 was observed after 72 h of treatment. Induction of mitogenesis in BAEC was significantly reduced by 25%-40% after treatment for 48-96 h with glycated (24 h) FGF-2 (gFGF-2; 100 pg/ml-5 ng/ml; P < 0.05), whilst capillary tubule formation was significantly reduced by between 60% and 90% (100 pg/ml-1 ng/ml; P < 0.05) after 5 days compared to native FGF-2. Subsequent investigation of the signal transduction molecules associated with mitogenesis showed a reduction in FGF-2 induced tyrosine phosphorylated proteins of approximate Mw 20-150 kDa between 10 min and 24 h, in particular, mitogen activated protein kinase (MAPK)/early response kinase (ERK-1, ERK-2), after glycation. To determine the reason for reduced angiogenic activity of gFGF-2, we compared its binding characteristics to that of native FGF-2. Total binding of gFGF-2 to the cell surface was significantly reduced in BAEC analysed by FACS compared to native FGF-2 (P < 0.05). Further investigation using 125I-labelled differentially washed samples, demonstrated a significant reduction in gFGF-2 binding to the high affinity tyrosine kinase receptor (46%) compared to native FGF-2. In summary, glycation of FGF-2 in vitro occurs rapidly within 24 h in the presence of elevated levels of G-6-P. Glycation caused a significant reduction in the ability of FGF-2 to bind to the tyrosine kinase receptor and activate signal transduction pathways responsible for both mitogenesis and capillary formation in BAEC. These results could help to explain the mechanism behind impaired wound healing in patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12197473     DOI: 10.1023/a:1016068917266

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  19 in total

1.  Altered ECM deposition by diabetic foot ulcer-derived fibroblasts implicates fibronectin in chronic wound repair.

Authors:  Anna G Maione; Avi Smith; Olga Kashpur; Vanessa Yanez; Elana Knight; David J Mooney; Aristidis Veves; Marjana Tomic-Canic; Jonathan A Garlick
Journal:  Wound Repair Regen       Date:  2016-06-08       Impact factor: 3.617

Review 2.  Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.

Authors:  Nikolaos Papanas; Efstratios Maltezos
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

3.  Essential Role of IL-12 in Angiogenesis in Type 2 Diabetes.

Authors:  Maha Ali; Vishal Mali; Samuel Haddox; Soad M AbdelGhany; Sahar E M El-Deek; Atif Abulfadl; Khalid Matrougui; Souad Belmadani
Journal:  Am J Pathol       Date:  2017-08-22       Impact factor: 4.307

4.  Evaluation of wound healing activity of ferulic acid in diabetic rats.

Authors:  Mahesh M Ghaisas; Shashank B Kshirsagar; Rajkumari S Sahane
Journal:  Int Wound J       Date:  2012-12-12       Impact factor: 3.315

Review 5.  Numerous isoforms of Fgf8 reflect its multiple roles in the developing brain.

Authors:  N Abimbola Sunmonu; Kairong Li; James Y H Li
Journal:  J Cell Physiol       Date:  2011-07       Impact factor: 6.384

6.  Chronic hyperglicemia and nitric oxide bioavailability play a pivotal role in pro-atherogenic vascular modifications.

Authors:  Assunta Pandolfi; Elena Anna De Filippis
Journal:  Genes Nutr       Date:  2007-10-17       Impact factor: 5.523

7.  Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: comparison with aminoguanidine.

Authors:  Yasotha Duraisamy; John Gaffney; Mark Slevin; Christopher A Smith; Kenneth Williamson; Nessar Ahmed
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

Review 8.  Heart disease in diabetic patients.

Authors:  Mihaela C Blendea; Samy I McFarlane; Esma R Isenovic; Gregory Gick; James R Sowers
Journal:  Curr Diab Rep       Date:  2003-06       Impact factor: 4.810

Review 9.  Inflammation and neuropeptides: the connection in diabetic wound healing.

Authors:  Leena Pradhan; Christoph Nabzdyk; Nicholas D Andersen; Frank W LoGerfo; Aristidis Veves
Journal:  Expert Rev Mol Med       Date:  2009-01-13       Impact factor: 5.600

10.  Hyperglycemic oxoaldehyde, glyoxal, causes barrier dysfunction, cytoskeletal alterations, and inhibition of angiogenesis in vascular endothelial cells: aminoguanidine protection.

Authors:  Sean M Sliman; Timothy D Eubank; Sainath R Kotha; M Lakshmi Kuppusamy; Shariq I Sherwani; Elizabeth Susan O'Connor Butler; Periannan Kuppusamy; Sashwati Roy; Clay B Marsh; David M Stern; Narasimham L Parinandi
Journal:  Mol Cell Biochem       Date:  2009-07-08       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.